Zhejiang Huaye Plastics Machinery
301616
Alnera Aluminium
301613
Glory View Technology
301396
4
Guangzhou Sie Consulting
300687
5
Tibet Duo Rui Pharmaceutical
301075
CN Stock MarketDetailed Quotes
002198 Guangdong Jiaying Pharmaceutical
- 7.11
- -0.14-1.93%
Market Closed Mar 31 15:00 CST
3.61BMarket Cap296.25P/E (TTM)
7.25High7.07Low73.14KlotVolume7.25Open7.25Pre Close52.13MTurnover1.44%Turnover Ratio104.56P/E (Static)507.51MShares9.3052wk High4.87P/B3.61BFloat Cap5.8352wk Low7.98Limit Up507.48MShs Float20.79Historical High6.53Limit Down2.48%Amplitude1.02Historical Low0.05Dividend TTM7.13Avg Price51.64KlotAsk0.70%Div YieldTTM100Lot Size20.43KlotBid
Guangdong Jiaying Pharmaceutical News
Guangdong Jiaying Pharmaceutical (002198.SZ): has not integrated the DeepSeek model or applied AI in the pharmaceutical field, and currently has no relevant plans.
On March 18, Gelonghui reported that Guangdong Jiaying Pharmaceutical (002198.SZ) stated on the investor interaction platform that the company is currently not using the DeepSeek model or applying AI in the pharmaceutical field, and there are no relevant plans at present. The company's main business is the research and development, production, and sales of Chinese Patent Medicine. The company will pay attention to the latest industry developments and carry out business in accordance with its own circumstances.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Guangdong Jiaying Pharmaceutical (002198.SZ): has repurchased a total of 1.416% of shares.
On February 6, Gelonghui reported that Guangdong Jiaying Pharmaceutical (002198.SZ) announced that as of January 31, 2025, the company had repurchased a total of 7,187,100 shares through a designated Share Buyback securities account via centralized bidding, accounting for 1.4161% of the company's current total share capital. The highest Fill Price for the buyback was 7.04 yuan per share, the lowest Fill Price was 6.78 yuan per share, and the total amount of the buyback was 49.46925 million yuan (excluding transaction fees).
The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.
① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.
Guangdong Jiaying Pharmaceutical (002198.SZ): Share buyback has not yet been implemented.
Gelonghui, January 2nd丨Guangdong Jiaying Pharmaceutical (002198.SZ) announced that as of December 31, 2024, the company has not implemented a share buyback.
Jiaying Pharmaceutical to Buy Back Up to 132 Million Yuan of Shares
Guangdong Jiaying Pharmaceutical (002198.SZ): Plans to launch the 2024 employee stock ownership plan with a total fundraising amount not exceeding 60.615 million yuan.
On December 13, Gelonghui announced that Guangdong Jiaying Pharmaceutical (002198.SZ) has released a draft for the 2024 employee stock ownership plan. This plan aims to raise a total of no more than 60.615 million yuan, with each unit valued at 1 yuan, reserving 11.8536 million units. The upper limit for the number of units in this employee stock ownership plan is 60.615 million units, and the final total amount raised will be based on the actual fundraising total. The stocks for this employee stock ownership plan are sourced from the company's repurchase of Guangdong Jiaying Pharmaceutical A-share common stocks from the secondary market, and the number of stocks intended to be held in this plan is not specified.
There's Reason For Concern Over Guangdong Jiaying Pharmaceutical Co., Ltd's (SZSE:002198) Massive 26% Price Jump
Jiaying Pharmaceutical: Report for the third quarter of 2024
Guangdong Jiaying Pharmaceutical (002198.SZ): The net income for the first three quarters was 2.8733 million yuan, a year-on-year decrease of 88.46%.
Jiaying Pharmaceutical (002198.SZ) announced its third quarter report for 2024 on October 30th. The company achieved revenue of 0.26 billion yuan in the first three quarters of the year, a decrease of 31.18% year-on-year; the net income attributable to shareholders of the listed company was 2.8733 million yuan, a decrease of 88.46% year-on-year; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -1.879 million yuan; basic earnings per share were 0.0057 yuan.
Guangdong Jiaying Pharmaceutical (002198.SZ): Orient, a shareholder owning more than 5% of the shares, plans to reduce its shareholding by no more than 1% of the company's shares.
Guangdong Jiaying Pharmaceutical (002198.SZ) announced on October 16 that shareholder Orient currently holds 57,223,000 shares of the company (accounting for 11.28% of the total share capital). Orient plans to reduce its shareholding by 5,075,098 shares (not exceeding 1% of the total share capital) through centralized competitive bidding trading within three months after fifteen trading days from the date of this shareholding reduction plan announcement.
Guangdong Jiaying Pharmaceutical Co., Ltd's (SZSE:002198) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?
Jiaying Pharmaceuticals: Semi-Annual Report 2024
Jiaying Pharmaceutical: 2024 Semi-Annual Report Summary
Guangdong Jiaying Pharmaceutical (002198.SZ): the net income in the first half of the year was 5.6677 million yuan, a year-on-year decrease of 68.94%.
Guangdong Jiaying Pharmaceutical (002198.SZ) announced its semi-annual report for 2024, with total operating revenue of 0.18 billion yuan, a decrease of 30.00% compared to the same period last year; net income attributable to shareholders of the listed company was 5.6677 million yuan, a decrease of 68.94% compared to the same period last year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.1626 million yuan, a decrease of 93.07% compared to the same period last year; basic earnings per share of 0.0112 yuan.
Guangdong Jiaying Pharmaceutical (002198.SZ) released its half-year performance with a net income of 5.6677 million yuan, a decrease of 68.94%.
Guangdong Jiaying Pharmaceutical (002198.SZ) released its 2024 interim report, during the reporting period, the company achieved revenue...
By August 9, 2024, the number of shareholders of Guangdong Jiaying Pharmaceutical (002198.SZ) was 22,367.
Guangdong Jiaying Pharmaceutical (002198.SZ) stated on the investor interaction platform on August 12 that as of August 9, 2024, according to the shareholder list issued by China Clearing, the number of shareholders of the company is 22,367.
The function and indication of Guangdong Jiaying Pharmaceutical (002198.SZ) Double-Throat Wind-Dispersing Granules are clearing heat and detoxifying, reducing swelling and benefiting the throat.
Guangdong Jiaying Pharmaceutical (002198.SZ) stated on the investor interaction platform on July 17 that the dual-purpose throat and wind dispersal produced by the company has the following functions: clearing heat and detoxifying, reducing swelling and soothing the throat. It is used for throat and mouth ulcers, gum swelling and pain, sinusitis, skin ulcers and other conditions caused by lung and stomach fever and toxicity.
As of July 10th, Guangdong Jiaying Pharmaceutical (002198.SZ) had a total of 22,404 shareholders.
On July 12th, Gelunhui reported that Guangdong Jiaying Pharmaceutical (002198.SZ) stated on the investor interaction platform that as of July 10, 2024, according to the shareholder roster issued by the China Securities Depository and Clearing Co., Ltd., the company has 22,404 shareholders.
Subdued Growth No Barrier To Guangdong Jiaying Pharmaceutical Co., Ltd's (SZSE:002198) Price